Know Cancer

or
forgot password


Phase 3
18 Years
90 Years
Open (Enrolling)
Both
Hemoptisis

Thank you

Trial Information


Inclusion Criteria:



- Age > 18

- Hemodynamicaly stable

- Hemoptysis of varying etiologies

- Coumadin treatment will be switched to clexane or heparine

Exclusion Criteria:

- Age < 18

- Hemodinamicaly unstable

- Massive hemoptysis ( > 200 ml / day)

- Renal failure: creatinine > 3, renal replacement treatment

- Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level

- Coagulation disorders, INR> 2.

- Hypesensitivity to tranexamic acid

- Pregnant woman

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

bleeding stops

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

David Shitrit, Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Meir Medical Center, Kfar Saba, Israel

Authority:

Israel: Ethics Commission

Study ID:

0096-11-MMC

NCT ID:

NCT01496196

Start Date:

January 2012

Completion Date:

February 2014

Related Keywords:

  • Hemoptisis
  • hemoptisis
  • bleeding
  • tranexamic acid

Name

Location